I certainly agree with the first bullet. As to the third bullet, I had a little over half my shares in the warrants and I sold all my warrants the day after FX results were published. And I will be very pissed if they extend the term. Also I agree with your fourth bullet. That retention bonus continues to give off a pretty bad smell.
Maybe they should have fired Traber instead of Czirr but given the problems we are currently facing, which began before Czirr was canned; more likely they should have both been terminated. 1) There were no safety issues identified at 8mg so it is unbelievable that higher doses (and increased frequency of dosing) were not tested in our Phase 1. 2) And Traber is now saying that the FX trial was done primarily to test non-invasive diagnostic tools and that therefore the FX trial was not designed to advance GR-MD-02 with the FDA. That means the FX trial was an irresponsible waste of scarce company resources!